Bioequivalence and Bioavailability Forum 15:34 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Ramesh Ramalingam
Junior

India,
2018-06-18 08:00

Posting: # 18913
Views: 618
 

 > 5% of Cmax for endogenous molecule? [Regulatives / Guidelines]

Dear All,

As per guidelines, Subjects with non-zero baseline concentrations > 5% of Cmax. Such data should be excluded from bioequivalence calculation.

Is it applicable for endogenous molecule? could you please suggest anyone..



Regards,
Ramesh. R
Helmut
Hero
avatar
Homepage
Vienna, Austria,
2018-06-18 10:59

@ Ramesh Ramalingam
Posting: # 18914
Views: 521
 

 Any own thoughts?

Hi Ramesh,

» As per guidelines, Subjects with non-zero baseline concentrations > 5% of Cmax. Such data should be excluded from bioequivalence calculation.
» Is it applicable for endogenous molecule?

All your posts are in the category Regulatives / Guidelines.
Remember that our job is not exegesis but science. Hence, what do you think?

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
Ramesh Ramalingam
Junior

India,
2018-08-08 07:29

@ Helmut
Posting: # 19159
Views: 205
 

 carryover effect in endogenous substances

Dear Helmut,

As per previous discussion. We con't directly assess the carry-over effect for endogenous substances. As per USFDA regulatory requirement we have to approach the concept of 5% cmax for endogenous substances also https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM234960.pdf. but they are not clearly telling about how to approach these concept for endogenous substances.

Kindly share your suggestions about to below statements.
When dealing with endogenous substances, the presence of carry-over effects is very difficult to quantify. Therefore to find a proof of absence or presence of carryover effect in endogenous substances, the pre-dose (baseline) drug concentrations for Period 1 should compared to the pre-dose concentrations for Period 2. Thus, previous period average pre-dose concentration should be subtracted with subsequent period average pre-dose concentration after that the resulted values should compare with 5% of cmax. Based on this we can ensure the carry over effect occurred or not in period 1 or in subsequent period.


Regards,
Ramesh.R
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,617 posts in 3,961 threads, 1,210 registered users;
online 21 (1 registered, 20 guests [including 16 identified bots]).

The only way to comprehend what mathematicians mean by Infinity
is to contemplate the extent of human stupidity.    Voltaire

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed